anti-cd30 car t cells

**Anti-CD30 CAR T cells** are autologous chimeric antigen receptor T cell therapies genetically engineered to target **CD30** antigen, which is expressed on the surface of malignant cells in classical Hodgkin lymphoma (cHL), anaplastic large cell lymphoma (ALCL), and some other lymphomas. The mechanism involves isolating patient T cells, transducing them with a viral vector encoding a CAR that recognizes CD30, expanding them in vitro, and re-infusing them after lymphodepleting chemotherapy. These CAR T cells bind CD30+ tumor cells, activate cytotoxicity, and induce antitumor effects independent of MHC recognition. Clinical studies show high overall response rates with limited toxicities in relapsed/refractory CD30+ lymphomas, especially when used with fludarabine-based lymphodepletion. Strategies involving combination with PD-1 blockade have been shown to enhance efficacy.

Other names

cd30.car-tcd-30.car-tcd 30.car-tcd30-directed car-t cellscd-30-directed car-t cellscd 30-directed car-t cellscd30 car t cellscd-30 car t cellscd 30 car t cells